Literature DB >> 27237103

Is Total Risk Management an Answer for Better Prognosis in Diabetic Patients?

Kenichi Sakakura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27237103      PMCID： PMC7399294          DOI： 10.5551/jat.ED050

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.928


× No keyword cloud information.
  10 in total

1.  Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Linda L Humphrey; Donna E Sweet; Melissa Starkey; Paul Shekelle
Journal:  Ann Intern Med       Date:  2012-02-07       Impact factor: 25.391

2.  Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study.

Authors:  Gillian L Booth; Moira K Kapral; Kinwah Fung; Jack V Tu
Journal:  Lancet       Date:  2006-07-01       Impact factor: 79.321

3.  Impact of type 2 diabetes on serial changes in tissue characteristics of coronary plaques: an integrated backscatter intravascular ultrasound analysis.

Authors:  Shinji Inaba; Hideki Okayama; Jun-ichi Funada; Haruhiko Higashi; Makoto Saito; Toyofumi Yoshii; Go Hiasa; Takumi Sumimoto; Yasunori Takata; Kazuhisa Nishimura; Katsuji Inoue; Akiyoshi Ogimoto; Jitsuo Higaki
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-02-24       Impact factor: 6.875

4.  Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group.

Authors:  I Gustafsson; C Torp-Pedersen; L Køber; F Gustafsson; P Hildebrandt
Journal:  J Am Coll Cardiol       Date:  1999-07       Impact factor: 24.094

5.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

6.  Impact of Total Risk Management on Coronary Plaque Regression in Diabetic Patients with Acute Coronary Syndrome.

Authors:  Ryo Naito; Katsumi Miyauchi; Hiroyuki Daida; Takeshi Morimoto; Takafumi Hiro; Takeshi Kimura; Yoshihisa Nakagawa; Masakazu Yamagishi; Yukio Ozaki; Masunori Matsuzaki
Journal:  J Atheroscler Thromb       Date:  2016-03-08       Impact factor: 4.928

7.  Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial).

Authors:  Takafumi Hiro; Takeshi Kimura; Takeshi Morimoto; Katsumi Miyauchi; Yoshihisa Nakagawa; Masakazu Yamagishi; Yukio Ozaki; Kazuo Kimura; Satoshi Saito; Tetsu Yamaguchi; Hiroyuki Daida; Masunori Matsuzaki
Journal:  Circ J       Date:  2010-05-12       Impact factor: 2.993

8.  Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).

Authors:  Takafumi Hiro; Takeshi Kimura; Takeshi Morimoto; Katsumi Miyauchi; Yoshihisa Nakagawa; Masakazu Yamagishi; Yukio Ozaki; Kazuo Kimura; Satoshi Saito; Tetsu Yamaguchi; Hiroyuki Daida; Masunori Matsuzaki
Journal:  J Am Coll Cardiol       Date:  2009-07-21       Impact factor: 24.094

9.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

10.  Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.

Authors:  Sabina A Murphy; Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Jennifer A White; Yuliya Lokhnygina; Craig Reist; KyungAh Im; Erin A Bohula; Daniel Isaza; Jose Lopez-Sendon; Mikael Dellborg; Uma Kher; Andrew M Tershakovec; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2016-02-02       Impact factor: 24.094
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.